CSL pays $11.7bn for new blood
The biggest biopharma deal of the year is also the biggest the Australian group has ever done.
Angion’s kidney transplant dream dies
The group will have to pivot to a heart surgery setting, but the omens here are not good. Meanwhile, Vifor’s run of bad luck continues.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Panel puts Fibrogen project to an almost certain death
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…
